Figure S1, Figure S2, Figure S3, Figure S4, Figure S5 from Adavosertib Enhances Antitumor Activity of Trastuzumab Deruxtecan in HER2-Expressing Cancers
<p>Supplemental Figures 1 - 5</p>
Gardado en:
| Autor Principal: | Timothy P. DiPeri (16384177) (author) |
|---|---|
| Outros autores: | Kurt W. Evans (16384180) (author), Maria Gabriela Raso (15107821) (author), Ming Zhao (16384183) (author), Yasmeen Q. Rizvi (16384186) (author), Xiaofeng Zheng (16384189) (author), Bailiang Wang (16384192) (author), Bryce P. Kirby (16384195) (author), Kathleen Kong (16384198) (author), Michael Kahle (16384201) (author), Timothy A. Yap (15028749) (author), Ecaterina E. Dumbrava (16384204) (author), Jaffer A. Ajani (11016306) (author), Siqing Fu (15047712) (author), Khandan Keyomarsi (14958560) (author), Funda Meric-Bernstam (10258780) (author) |
| Publicado: |
2025
|
| Subjects: | |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|
Títulos similares
-
Figures S1-S2 from Preclinical and Clinical Efficacy of Trastuzumab Deruxtecan in Breast Cancer Brain Metastases
por: Sheheryar Kabraji (15050565)
Publicado: (2025) -
Figure 2 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
por: Nigel Bundred (15046233)
Publicado: (2025) -
Figure 1 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
por: Nigel Bundred (15046233)
Publicado: (2025) -
Figure 3 from Combined Perioperative Lapatinib and Trastuzumab in Early HER2-Positive Breast Cancer Identifies Early Responders: Randomized UK EPHOS-B Trial Long-Term Results
por: Nigel Bundred (15046233)
Publicado: (2025) -
Figure S2 from A Multiparameter Molecular Classifier to Predict Response to Neoadjuvant Lapatinib plus Trastuzumab without Chemotherapy in HER2<sup>+</sup> Breast Cancer
por: Jamunarani Veeraraghavan (16461809)
Publicado: (2025)